INTERVENTION 1:	Intervention	0
HR+, HER2-	Intervention	1
Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.	Intervention	2
hormone	CHEBI:24621	14-21
receptor	BAO:0000281	22-30
breast cancer	DOID:1612	55-68
cyclophosphamide	CHEBI:4026	159-175
INTERVENTION 2:	Intervention	3
Triple Negative Breast Cancer Cohort	Intervention	4
breast cancer	DOID:1612	16-29
Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.	Intervention	5
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
drug	CHEBI:23888	62-66
Inclusion Criteria:	Eligibility	0
Documented primary invasive breast cancer by histologic assessment	Eligibility	1
breast cancer	DOID:1612	28-41
Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis	Eligibility	2
estrogen	CHEBI:50114,BAO:0000760	20-28
progesterone	CHEBI:17026	41-53
Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol	Eligibility	3
breast cancer	DOID:1612	40-53
18 year of age or older	Eligibility	4
year	UO:0000036	3-7
age	PATO:0000011	11-14
Performance status of 0 or 1 by ECOG criteria	Eligibility	5
Use of an effective means of contraception in subjects of childbearing potential	Eligibility	6
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy.	Eligibility	7
Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment	Eligibility	8
hormone	CHEBI:24621	38-45
time	PATO:0000165	79-83
Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer	Eligibility	9
breast cancer	DOID:1612	81-94
No other malignancy that requires on-going treatment	Eligibility	10
Normal organ function as outlined in the protocol	Eligibility	11
organ	UBERON:0000062	7-12
function	BAO:0003117,BFO:0000034	13-21
Exclusion Criteria:	Eligibility	12
Prior cytotoxic chemotherapy or radiation for the current breast cancer	Eligibility	13
breast cancer	DOID:1612	58-71
Patients with inflammatory breast cancer	Eligibility	14
breast cancer	DOID:1612	27-40
HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH	Eligibility	15
disease	DOID:4,OGMS:0000031	14-21
Known metastatic (Stage IV) disease	Eligibility	16
disease	DOID:4,OGMS:0000031	28-35
Other investigational agents within 4 weeks prior to the start of study treatment	Eligibility	17
Life expectancy of less than 6 months	Eligibility	18
Peripheral neuropathy greater than or equal to grade 2	Eligibility	19
peripheral neuropathy	HP:0009830,DOID:870	0-21
Inadequately controlled hypertension	Eligibility	20
hypertension	HP:0000822,DOID:10763	24-36
Any prior history of hypertensive crisis or hypertensive encephalopathy	Eligibility	21
history	BFO:0000182	10-17
hypertensive crisis	HP:0100735	21-40
hypertensive encephalopathy	DOID:9427	44-71
NYHA grade II or greater congestive heart failure	Eligibility	22
congestive heart failure	HP:0001635,DOID:6000	25-49
History of prior myocardial infarction	Eligibility	23
history	BFO:0000182	0-7
myocardial infarction	HP:0001658,DOID:5844	17-38
History of unstable angina within 12 months prior to study enrollment	Eligibility	24
history	BFO:0000182	0-7
Any history of stroke or transient ischemic attack at any time	Eligibility	25
history	BFO:0000182	4-11
stroke	HP:0001297,DOID:6713	15-21
transient ischemic attack	HP:0002326,DOID:224	25-50
time	PATO:0000165	58-62
Known CNS disease	Eligibility	26
disease	DOID:4,OGMS:0000031	10-17
Significant vascular disease	Eligibility	27
vascular disease	DOID:178	12-28
Symptomatic peripheral vascular disease	Eligibility	28
peripheral vascular disease	DOID:341	12-39
Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study.	Eligibility	29
bone fracture	HP:0020110	106-119
abscess	HP:0025615	192-199
surgery	OAE:0000067	327-334
Known HIV positive	Eligibility	30
Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue	Eligibility	31
tissue	UBERON:0000479	80-86
Pregnant of lactating	Eligibility	32
Known hypersensitivity to any component of bevacizumab	Eligibility	33
hypersensitivity	GO:0002524,DOID:1205	6-22
Outcome Measurement:	Results	0
Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.	Results	1
rate	BAO:0080019	29-33
patient	HADO:0000008,OAE:0001817	69-76
Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery	Results	2
breast	UBERON:0000310	93-99
time	PATO:0000165	107-111
surgery	OAE:0000067	115-122
Time frame: 3 Years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: HR+, HER2-	Results	5
Arm/Group Description: Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.	Results	6
hormone	CHEBI:24621	37-44
receptor	BAO:0000281	45-53
breast cancer	DOID:1612	78-91
cyclophosphamide	CHEBI:4026	182-198
Overall Number of Participants Analyzed: 84	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  8	Results	9
Results 2:	Results	10
Arm/Group Title: Triple Negative Breast Cancer Cohort	Results	11
breast cancer	DOID:1612	33-46
Arm/Group Description: Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.	Results	12
hormone	CHEBI:24621	23-30
receptor	BAO:0000281	31-39
drug	CHEBI:23888	85-89
Overall Number of Participants Analyzed: 20	Results	13
Measure Type: Number	Results	14
Unit of Measure: percentage of participants  44	Results	15
Adverse Events 1:	Adverse Events	0
Total: 4/104 (3.85%)	Adverse Events	1
Neutropenia 1/104 (0.96%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
Leukopenia 2/104 (1.92%)	Adverse Events	3
leukopenia	HP:0001882,DOID:615	0-10
paranasal sinus reaction 1/104 (0.96%)	Adverse Events	4
cellulitis 1/104 (0.96%)	Adverse Events	5
cellulitis	HP:0100658,DOID:3488	0-10
Adverse Events 2:	Adverse Events	6
